Business Context and Reporting Period
This Form 8-K is a current report filed by BeiGene, Ltd. on January 29, 2021. The filing announces that the Shanghai Stock Exchange (SSE) has accepted the Company's Listing Application for a proposed public offering of ordinary shares on the Science and Technology Innovation Board (STAR Market) in China. The report details the terms of this proposed offering, referred to as the "STAR Offering," and the issuance of new shares denominated in Renminbi ("RMB Shares").
Key Financial Metrics and Offering Terms
The filing does not report standard quarterly revenue, profit, or cash flow metrics for the Company. Instead, it outlines the financial parameters of the proposed STAR Offering:
- Offering Size: Up to 132,313,549 ordinary shares (including over-allotment), representing no more than 10% of the total issued ordinary shares as of January 7, 2021, plus the new shares.
- Target Proceeds: The Company assumes net proceeds of RMB 20 billion (approximately USD 3.1 billion) for planning purposes.
- Use of Proceeds:
- Clinical development and research projects: 66%
- Replenishment of working capital: 30%
- Research and development center construction: 2%
- Bio-manufacturing plant construction: 1%
- Sales and marketing force expansion: 1%
- Accounting Standards: The Listing Application includes financial information prepared under PRC GAAP for the years ended December 31, 2017, 2018, 2019, and the nine months ended September 30, 2020. A reconciliation to U.S. GAAP is provided in Exhibit 99.1.
Material Changes and Share Structure
The filing details a significant structural change regarding the Company's share classes:
- New Share Class: The RMB Shares will be ordinary shares ranking pari passu with existing offshore shares (listed in Hong Kong and as ADSs on NASDAQ) regarding voting and asset rights.
- Non-Fungibility: The RMB Shares will be registered on a separate PRC register and will not be fungible with offshore shares. They cannot be moved outside the PRC or traded on the Hong Kong Stock Exchange or NASDAQ.
- Shareholder Approval: The offering is subject to a "Specific Mandate" to be approved by shareholders at an Extraordinary General Meeting (EGM).
Outlook, Risks, and Contingencies
The consummation of the STAR Offering is contingent upon several factors:
- Regulatory Approvals: Approval from the China Securities Regulatory Commission (CSRC) and the SSE is required.
- Shareholder Approval: Shareholders must approve the Specific Mandate and amendments to the Articles of Association at the EGM.
- Market Conditions: The Board may decide not to proceed if the offer price is deemed unfavorable compared to trading prices of ADSs or Hong Kong shares.
- Risks: The filing includes standard forward-looking statement disclaimers regarding the uncertainty of the offering materializing, clinical trial results, regulatory actions, and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the final offer price once determined by the Pricing Committee and compare it to current ADS and Hong Kong share trading prices.
- Review the upcoming Proxy Statement/Circular for the EGM to understand the Specific Mandate and proposed amendments to the Articles of Association.
- Confirm the status of regulatory approvals from the SSE and CSRC, as the offering is not guaranteed.
- Examine Exhibit 99.1 for the reconciliation of PRC GAAP financial data to U.S. GAAP to understand historical R&D expenses.
- Monitor announcements regarding the timing of the EGM and the final decision on whether to proceed with the offering.